Variational Bayesian Multi-Kernel Adaptive Deep Fusion for Microbe-Related Drug Prediction

Read full text
Authors: Yingjun Ma, Yingjun Ma, 罗明绪, Liyu Yan, Yuanyuan Ma, Yuanyuan Ma
Cited by: 1
References: 47

Abstract

Exploring potential microbe-drug associations (MDAs) not only facilitates drug discovery and clinical treatment but also contributes to a deeper understanding of microbial mechanisms. However, most MDA discoveries rely on biological experiments, which are time-consuming and costly. Therefore, developing an effective computational model to predict novel MDAs is of great importance. In this study, we propose a Variational Bayesian Multi-Kernel Adaptive Deep Fusion (VBMKADF) model for MDA prediction. We first integrate multiomics data to construct drug molecular graphs and a microbe hypergraph. Then, we perform multilayer graph convolution and hypergraph convolution to extract multilevel similarities of drugs and microbes, respectively. An attention mechanism is subsequently introduced to adaptively fuse these multilevel similarities, which are then incorporated into the Bayesian logistic matrix factorization framework to guide the generation of latent variable distributions. Additionally, we develop a variational Expectation-Maximization algorithm for adaptive inference of model hyperparameters and latent variables, which also guides the training of the deep learning model. Experimental results on two benchmark data sets across three scenarios show that, compared to other state-of-the-art methods, VBMKADF achieves higher AUPR, AUC, and F1 scores in both balanced and highly imbalanced settings. Moreover, case studies further confirm that VBMKADF can serve as an effective tool for MDA prediction.

Fields of Study & Subjects

Computational Drug Discovery Methods Machine Learning in Bioinformatics vaccines and immunoinformatics approaches

Publication details

Journal / source
Journal of Chemical Information and Modeling
Publisher
American Chemical Society (ACS)
Volume
66
Issue
4
Pages
2410–2425
Publication date
2 February 2026
Language
EN